Nasal toxicity of Benzalkonium chloride

American Journal of Rhinology

Volumn 18, Issue 5, 2004, Pages 291-299

  Riechelmann, Herbert ^a   Deutschle, Tom ^a   Stuhlmiller, Anja ^a   Gronau, Silke ^a   Bürner, Herald ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; CYTOKINE; INTERLEUKIN 6; MYELOPEROXIDASE; NEUROPEPTIDE; NOSE SPRAY; PLACEBO; RINGER SOLUTION; SACCHARIN; SUBSTANCE P;

ARTICLE; BURNING SENSATION; CELL ISOLATION; CELL STRUCTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE RELEASE; DONOR; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; NORMAL HUMAN; NOSE IRRITATION; NOSE MUCOSA; NOSE SECRETION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; TOXICITY;

EID: 10244242456     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.1177/194589240401800506     Document Type: Article

References (60)

1. Merianos J. Surface-active agents. In Disinfection, Sterilization, and Preservation. Block SS (Ed). Philadelphia, PA: Lippincott Williams & Wilkins, 283-320, 2001.
2. Gardner P, and Girard E. Analyis of common household cleaner-disinfectants by capillary electrophoresis. J Chem Ed 77:1335-1338, 2000.
3. Jono K, Takayama T, Kuno M, et al. Effect of alkyl chain length of benzalkonium chloride on the bactericidal activity and binding to organic materials. Chem Pharm Bull 34:4215-4224, 1986.
4. Adriaens E, Dierckens K, Bauters TG, et al. The mucosal toxicity of different benzalkonium chloride analogues evaluated with an alternative test using slugs. Pharm Res 18:937-942, 2001.
5. Patarca R, Rosenzweig JA, Zuniga AA, et al. Benzalkonium salts: effects on G protein-mediated processes and surface membranes. Crit Rev Oncog 11:255-305, 2000.
6. Beasley R, Burgess C, and Holt S. Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions. J Allergy Clin Immunol 107:222-223, 2001.
7. Hallen H, Enerdal J, and Graf P. Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa. Clin Exp Allergy 27:552-558, 1997.
8. Cho JH, Kwun YS, Jang HS, et al. Long-term use of preservatives on rat nasal respiratory mucosa: Effects of benzalkonium chloride and potassium sorbate. Laryngoscope 110:312-317, 2000.
9. Berg OH, Henriksen RN, and Steinsvag SK. The effect of a benzalkonium chloride-containing nasal spray on human respiratory mucosa in vitro as a function of concentration and time of action. Pharmacol Toxicol 76:245-249, 1995.
10. van de Donk HJ, van den Heuvel AG, Zuidema J, et al. The effects of nasal drops and their additives on human nasal mucociliary clearance. Rhinology 20:127-137, 1982.
11. Hofmann T, Wolf G, and Koidl B. Effect of topical corticosteroids and topical antihistaminics on ciliary epithelium of human nasal mucosa in vitro. HNO 46:146-151, 1998.
12. Alberty J, and Stoll W. The effect of antiallergic intranasal formulations on ciliary beat frequency of human nasal epithelium in vitro. Allergy 53:986-989, 1998.
13. van de Donk HJ, Muller Plantema IP, Zuidema J, et al. The effects of preservatives on the ciliary beat frequency of chicken embryo tracheas. Rhinology 18:119-133, 1980.
14. Boek WM, Romeijn SG, Graamans K, et al. Validation of animal experiments on ciliary function in vitro. II. The influence of absorption enhancers, preservatives, and physiologic saline. Acta Otolaryngol 119:98-101, 1999.
15. Merkus F, Romeijn S, Verhorf J, et al. The effect of nasal drug formulations on ciliary beating in vitro. Int J Pharm 135:137-145, 1996.
16. Joki S, Saano V, Nuutinen J, et al. Effects of some preservative agents on rat and guinea pig tracheal and human nasal ciliary beat frequency. Am J Rhinology 10:181-186, 1996.
17. Stanley PJ, Griffin WM, Wilson R, et al. Effect of betamethasone and betamethasone with neomycin nasal drops on human nasal mucociliary clearance and ciliary beat frequency. Thorax 40: 607-612, 1985.
18. Batts AH, Marriott C, Martin GP, et al. The effect of some preservatives used in nasal preparations on the mucus and ciliary components of mucociliary clearance. J Pharm Pharmacol 42: 145-151, 1990.
19. Kuboyama Y, Suzuki K, and Hara T. Nasal lesions induced by intranasal administration of benzaikonium chloride in rats. J Toxicol Sci 22:153-160, 1997.
20. Cureoglu S, Akkus M, Osma U, et al. The effect of benzalkonium chloride on rabbit nasal mucosa in vivo: An electron microscopy study. Eur Arch Otorhinolaryngol 259:362-364, 2002.
21. McMahon C, Darby Y, Ryan R, et al. Immediate and short-term effects of benzalkonium chloride on the human nasal mucosa in vivo. Clin Otolaryngol 22:318-322, 1997.
22. Braat JP, Ainge G, Bowles JA, et al. The lack of effect of benzalkonium chloride on the cilia of the nasal mucosa in patients with perennial allergic rhinitis: A combined functional, light, scanning, and transmission electron microscopy study. Clin Exp Allergy 25:957-965, 1995.
23. Batts AH, Marriott C, Martin GP, et al. The use of a radiolabelled saccharin solution to monitor the effect of the preservatives thiomersal, benzalkonium chloride, and EDTA on human nasal clearance. J Pharm Pharmacol 43:180-185, 1991.
24. Steinsvag SK, Bjerknes R, and Berg OH. Effects of topical nasal steroids on human respiratory mucosa and human granulocytes in vitro. Acta Otolaryngol 116:868-875, 1996.
25. Hakansson L, Rak S, Dahl R, et al. The formation of eosinophil and neutrophil chemotactic activity during a pollen season and after allergen challenge. J Allergy Clin Immunol 83:933-939, 1989.
26. Boston M, Dobratz EJ, and Darrow DH. Effects of nasal saline spray on human neutrophils. Presented at the 104th Annual Meeting of the Triological Society, Palm Desert, CA, May 15, 2001 and 2003.
27. Wilmer JL, Burleson FG, Kayama F, et al. Cytokine induction in human epidermal keratinocytes exposed to contact irritants and its relation to chemical-induced inflammation in mouse skin. J Invest Dermatol 102:915-922, 1994.
28. Holliday MR, Dearman RJ, Corsini E, et al. Selective stimulation of cutaneous interleukin 6 expression by skin allergens. J Appl Toxicol 16:65-70, 1996.
29. Muller-Decker K, Heinzelmann T, Furstenberger G, et al. Arachidonic acid metabolism in primary irritant dermatitis produced by patch testing of human skin with surfactants. Toxicol Appl Pharmacol 153:59-67, 1998.
30. Britton B, Hervey R, Kasten K, et al. Intraocular irritation evaluation of benzalkonium chloride in rabbits. Ophthalmic Surg 7:46-55, 1976.
31. Krysiak B, Rydzynski K, and Kiec-Swierczynska M. The evaluation of the irritating and sensitizing effects of benzalkonium chloride. Med Pr 49:371-379, 1998.
32. Storaas T, Andersson M, Persson CG, et al. Effects of benzalkonium chloride on innate immunity physiology of the human nasal mucosa in vivo. Laryngoscope 110:1543-1547, 2000.
33. Bernstein IL. Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport. J Allergy Clin Immunol 105:39-44, 2000.
34. Meyer RJ. Comment on call for worldwide withdrawal of BAC from nebulizer solutions. J Allergy Clin Immumol 108:469-470, 2001.
35. Richards DH. Preservation of nasal sprays. J Allergy Clin Immunol 106:595-596, 2000.
36. Bommer R. Latest advances in nasal drug-delivery technology. Med Device Technol 10:22-28, 1999.
37. Riechelmann H, Klimek L, and Mann W. Objective measures of nasal function. Curr Opin Otolaryngol Head Neck Surg 3:207-213, 1995.
38. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 28: 577-584, 1972.
39. Senn S. Cross-over trials in clinical research. John Wiley & Sons, Chichester, U.K. 1993.
40. Hahn GJ, and Meeker WQ. Statistical intervals - a guide for practitioners. John Wiley & Sons, New York, 1991.
41. Naclerio RM, Baroody FM, de Tineo ML, et al. Nasal clearance after treatment with budesonide or mometasone. Presented at the 106th Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery, San Diego, CA, September 22-25, 2002 and 2003.
42. Read GW, and Kiefer EF. Benzalkonium chloride: Selective inhibitor of histamine release induced by compound 48/80 and other polyamines. J Pharmacol Exp Ther 211:711-715, 1979.
43. Fassihi R. Preservation and microbiological attributes of nonsterile pharmaceutical products. In Disinfection, Sterilization, and Preservation. Block SS (Ed). Philadelphia, PA: Lippincott Williams & Wilkins, 1263-1281, 2001.
44. van Klingeren B. Standard-suspension-test: Influence of bovine albumin, saline and water of standard hardness on M.E.-values. Zentralbl Bakteriol Mikrobiol Hyg [B] 176:63-71, 1982.
45. Langsrud S, and Sundheim G. Factors influencing a suspension test method for antimicrobial activity of disinfectants. J Appl Microbiol 85:1006-1012, 1998.
46. Messager S, Goddard PA, Dettmar PW, et al. Determination of the antibacterial efficacy of several antiseptics tested on skin by an "ex-vivo" test. J Med Microbiol 50:284-292, 2001.
47. Riechelmann H. The nose versus the environment: 1982 and today. Am J Rhinol 14:291-7, 2000.
48. Calderon MA, Devalia JL, Prior AJ, et al. A comparison of cytokine release from epithelial cells cultured from nasal biopsy specimens of atopic patients with and without rhinitis and nonatopic subjects without rhinitis. J Allergy Clin Immunol 99:65-76, 1997.
49. Kenney JS, Baker C, Welch MR, et al. Synthesis of interleukin-1 alpha, interleukin-6, and interleukin-8 by cultured human nasal epithelial cells. J Allergy Clin Immunol 93:1060-1067, 1994.
50. Baraniuk JN, and Kaliner M. Neuropeptides and nasal secretion. Am J Physiol 261:223-235, 1991.
51. Frosch PJ, and Czarnetzki BM. Surfactants cause in vitro chemotaxis and chemokinesis of human neutrophils. J Invest Dermatol 88:52s-55s, 1987.
52. Holliday MR, Corsini E, Smith S, et al. Differential induction of cutaneous TNF-alpha and IL-6 by topically applied chemicals. Am J Contact Dermat 8:158-164, 1997.
53. Corsini E, Primavera A, Marinovich M, et al. Selective induction of cell-associated interleukin-1alpha in murine keratinocytes by chemical allergens. Toxicology 129:193-200, 1998.
54. Grant S, Aitchison T, Henderson E, et al. A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest 116:1208-1217, 1999.
55. Nettis E, Colanardi MC, Soccio AL, et al. Occupational irritant and allergic contact dermatitis among healthcare workers. Contact Dermatitis 46:101-107, 2002.
56. Willis CM, Stephens JM, and Wilkinson JD. Experimentally induced irritant contact dermatitis. Determination of optimum irritant concentrations. Contact Dermatitis 18:20-24, 1988.
57. Furrer P, Plazonnet B, Mayer JM, et al. Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants. Int J Pharm 207:89-98, 2000.
58. Dusing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 3:488-492, 2001.
59. Hughes DA, Bagust A, Haycox A, et al. The impact of noncompliance on the cost-effectiveness of pharmaceuticals: A review of the literature. Health Econ 10:601-615, 2001.
60. Beasley R, Fishwick D, Miles JF, et al. Preservatives in nebulizer solutions: Risks without benefit. Pharmacotherapy 18:130-139, 1998.